NCT00817375

Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,000 (estimated)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 19 Years – 89 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether pharmacogenomic study predict antidepressant responsiveness in advance before the appearance of the drug effects until 4\~6 weeks after drug administration.

Detailed description

The purpose of this study is 1. to determine whether genomic effects on antidepressant response differed by class of drug, 2. whether genomic differences between drug responders and nonresponders predict the response of antidepressant and 3. to construct the prediction model for antidepressant treatment in order to aid to select the their genetically matching drugs.

Conditions

• Depression
• Adverse Reaction to Drug

Interventions

Type	Name	Description
DRUG	SSRI treated group	Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
DRUG	non-SSRI treated group	Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose

Timeline

• Start date: 2003-02-01
• Primary completion: 2018-12-01
• Completion: 2018-12-01
• First posted: 2009-01-06
• Last updated: 2015-12-31

Locations

1 site across 1 country: South Korea